Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 18:28 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3CompletedINTERVENTIONAL

A Comparison of PF708 and Forteo in Osteoporosis Patients

ClinicalTrials.gov · NCT03002428 · Registry updated: 2018-05-23

Condition / research focus: Osteoporosis
Sponsor: Pfenex, Inc
Countries with listed sites: United States
Registry dates and results: Start: 2016-12. Completion: 2018-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (PF708) (drug)
Teriparatide (Forteo) (drug)

Where the study takes place — 26 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Radiant Research
Birmingham, Alabama, United States
Site recruitment: Not reported
The Orthopaedic Group
Mobile, Alabama, United States
Site recruitment: Not reported
Radiant Research
Chandler, Arizona, United States
Site recruitment: Not reported
Radiant Research
Mesa, Arizona, United States
Site recruitment: Not reported
SunValley Arthritis Center
Peoria, Arizona, United States
Site recruitment: Not reported
Radiant Research
Phoenix, Arizona, United States
Site recruitment: Not reported
Radiant Research
Colorado Springs, Colorado, United States
Site recruitment: Not reported
OB-GYN Associates of Mid-Florida
Leesburg, Florida, United States
Site recruitment: Not reported
Atlanta Research Center
Atlanta, Georgia, United States
Site recruitment: Not reported
Radiant Research
Chicago, Illinois, United States
Site recruitment: Not reported
Radiant Research
Bridgeton, Missouri, United States
Site recruitment: Not reported
Radiant Research
Papillion, Nebraska, United States
Site recruitment: Not reported
Radiant Research
Henderson, Nevada, United States
Site recruitment: Not reported
Radiant Research
Las Vegas, Nevada, United States
Site recruitment: Not reported
New Mexico Clinical Research & Osteoporosis Center
Albuquerque, New Mexico, United States
Site recruitment: Not reported
Lillestol Research
Fargo, North Dakota, United States
Site recruitment: Not reported
Radiant Research
Akron, Ohio, United States
Site recruitment: Not reported
Radiant Research
Cincinnati, Ohio, United States
Site recruitment: Not reported
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
Site recruitment: Not reported
Pennsylvania Regional Center for Arthritis & Osteoporosis Research
Wyomissing, Pennsylvania, United States
Site recruitment: Not reported
Radiant Research
Dallas, Texas, United States
Site recruitment: Not reported
Radiant Research
Plano, Texas, United States
Site recruitment: Not reported
Radiant Research
San Antonio, Texas, United States
Site recruitment: Not reported
Radiant Research
San Antonio, Texas, United States
Site recruitment: Not reported
Spectrum Medical
Danville, Virginia, United States
Site recruitment: Not reported
Radiant Research
Puyallup, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Secondary Prevention of Osteoporotic Fractures: a Multiple Center Fracture Liaison Service in Greece

ClinicalTrials.gov · NCT02637180 · Registry updated: 2018-02-23

Condition / research focus: Osteoporosis
Sponsor: Hellenic Society for the Study of Bone Metabolism
Countries with listed sites: Greece
Registry dates and results: Start: 2015-04. Completion: 2017-12-07 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

anti-osteoporotic medication (drug) — also listed as: all available anti-osteoporotic medication

Where the study takes place — 4 listed sites

NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, MEDICAL SCHOOL, 2nd DEPARTMENT OF ORTHOPAEDIC SURGERY
Athens, Attica, Greece
Site recruitment: Not reported
Democritus University of Thrace, School of Medicine, Department of Orthopaedic Surgery
Alexandroupoli, Evros, Greece
Site recruitment: Not reported
Orthopaedic Department, Faculty of Medicine, School of Health Sciences, University of Thessalia
Larissa, Greece
Site recruitment: Not reported
Aristotle University of Thessaloniki, 3rd University Orthopaedic Department, Papageorgiou General Hospital
Thessaloniki, Greece
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

ClinicalTrials.gov · NCT01279187 · Registry updated: 2018-02-07

Condition / research focus: Implant
Sponsor: University of Michigan
Countries with listed sites: United States
Registry dates and results: Start: 2011-02. Completion: 2015-11 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug) — also listed as: Forteo
Placebo (drug) — also listed as: carrier

Where the study takes place — 1 listed sites

Michigan Center for Oral Health Research
Ann Arbor, Michigan, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects

ClinicalTrials.gov · NCT02571140 · Registry updated: 2018-01-10

Condition / research focus: Drug Safety and Bioavailability
Sponsor: Entera Bio Ltd.
Countries with listed sites: No country reported
Registry dates and results: Start: 2013-10. Completion: 2017-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug)
Oral PTH (1-34) (drug) — also listed as: Teriparatide

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Fracture (FX) Improvement With Teriparatide: FiX-IT Study

ClinicalTrials.gov · NCT01705587 · Registry updated: 2017-12-12

Condition / research focus: Osteoporosis; Atypical Femoral Fracture
Sponsor: Susan L. Greenspan
Countries with listed sites: United States
Registry dates and results: Start: 2012-12. Completion: 2016-09 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

teriparatide (drug) — also listed as: Forteo

Where the study takes place — 1 listed sites

University of Pittsburgh, Osteoporosis Prevention & Treatment Center
Pittsburgh, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.

ClinicalTrials.gov · NCT00471237 · Registry updated: 2017-11-07

Condition / research focus: Osteoporosis
Sponsor: GlaxoSmithKline
Countries with listed sites: Argentina · Australia · Belgium · Denmark · Germany · Hong Kong · Mexico · Norway · Poland · Russia · South Africa · South Korea · Spain · United States
Registry dates and results: Start: 2007-05-14. Completion: 2008-12-26 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ronacaleret (drug) — also listed as: SB-751689
Teriparatide (drug)
Alendronate (drug)

Where the study takes place — 49 listed sites

GSK Investigational Site
Oakland, California, United States
Site recruitment: Not reported
GSK Investigational Site
Palm Desert, California, United States
Site recruitment: Not reported
GSK Investigational Site
Walnut Creek, California, United States
Site recruitment: Not reported
GSK Investigational Site
Decatur, Georgia, United States
Site recruitment: Not reported
GSK Investigational Site
Bethesda, Maryland, United States
Site recruitment: Not reported
GSK Investigational Site
Akron, Ohio, United States
Site recruitment: Not reported
GSK Investigational Site
Cleveland, Ohio, United States
Site recruitment: Not reported
GSK Investigational Site
Portland, Oregon, United States
Site recruitment: Not reported
GSK Investigational Site
Duncansville, Pennsylvania, United States
Site recruitment: Not reported
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Site recruitment: Not reported
GSK Investigational Site
Buenos Aires, Argentina
Site recruitment: Not reported
GSK Investigational Site
Buenos Aires, Argentina
Site recruitment: Not reported
GSK Investigational Site
St Leonards, New South Wales, Australia
Site recruitment: Not reported
GSK Investigational Site
Footscray, Victoria, Australia
Site recruitment: Not reported
GSK Investigational Site
Geelong, Victoria, Australia
Site recruitment: Not reported
GSK Investigational Site
Heidelberg, Victoria, Australia
Site recruitment: Not reported
GSK Investigational Site
Ghent, Belgium
Site recruitment: Not reported
GSK Investigational Site
Liège, Belgium
Site recruitment: Not reported
GSK Investigational Site
Tienen, Belgium
Site recruitment: Not reported
GSK Investigational Site
Ballerup Municipality, Denmark
Site recruitment: Not reported
GSK Investigational Site
Frankfurt am Main, Hesse, Germany
Site recruitment: Not reported
GSK Investigational Site
Berlin, Germany
Site recruitment: Not reported
GSK Investigational Site
Berlin, Germany
Site recruitment: Not reported
GSK Investigational Site
Berlin, Germany
Site recruitment: Not reported
GSK Investigational Site
Berlin, Germany
Site recruitment: Not reported
GSK Investigational Site
Hamburg, Germany
Site recruitment: Not reported
GSK Investigational Site
Hamburg, Germany
Site recruitment: Not reported
GSK Investigational Site
Hong Kong, Hong Kong
Site recruitment: Not reported
GSK Investigational Site
Shatin, Hong Kong
Site recruitment: Not reported
GSK Investigational Site
Mexico City, Mexico
Site recruitment: Not reported
GSK Investigational Site
Bergen, Norway
Site recruitment: Not reported
GSK Investigational Site
Hamar, Norway
Site recruitment: Not reported
GSK Investigational Site
Oslo, Norway
Site recruitment: Not reported
GSK Investigational Site
Grudziądz, Poland
Site recruitment: Not reported
GSK Investigational Site
Warsaw, Poland
Site recruitment: Not reported
GSK Investigational Site
Wroclaw, Poland
Site recruitment: Not reported
GSK Investigational Site
Moscow, Russia
Site recruitment: Not reported
GSK Investigational Site
Moscow, Russia
Site recruitment: Not reported
GSK Investigational Site
Panorama, South Africa
Site recruitment: Not reported
GSK Investigational Site
Rosebank, South Africa
Site recruitment: Not reported
GSK Investigational Site
Somerset West, South Africa
Site recruitment: Not reported
GSK Investigational Site
Seoul, South Korea
Site recruitment: Not reported
GSK Investigational Site
Suwon, South Korea
Site recruitment: Not reported
GSK Investigational Site
Barcelona, Spain
Site recruitment: Not reported
GSK Investigational Site
Barcelona, Spain
Site recruitment: Not reported
GSK Investigational Site
Madrid, Spain
Site recruitment: Not reported
GSK Investigational Site
Madrid, Spain
Site recruitment: Not reported
GSK Investigational Site
Santiago de Compostela, Spain
Site recruitment: Not reported
GSK Investigational Site
Santiago de Compostela, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

ClinicalTrials.gov · NCT00542425 · Registry updated: 2017-10-30

Condition / research focus: Osteoporosis
Sponsor: Radius Health, Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2007-04. Completion: 2009-06 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

teriparatide (drug) — also listed as: PTH
Placebo (drug)
BA058 20 µg (drug)
BA058 40 µg (drug)
BA058 80 µg (drug)

Where the study takes place — 1 listed sites

Radius Health, Inc.
Cambridge, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab

ClinicalTrials.gov · NCT02130973 · Registry updated: 2017-08-31

Condition / research focus: Osteoporosis
Sponsor: Health Research, Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2013-08. Completion: 2018-08 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Standard Clinical Practice Regimen (drug) — also listed as: 18 months Forteo followed by 18 months Prolia
Experimental Cyclic Regimen (drug) — also listed as: three separate 6 month cycles of daily Forteo, each followed by one of Prolia

Where the study takes place — 1 listed sites

Helen Hayes Hospital
West Haverstraw, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Cyclic Versus Daily Teriparatide on Bone Mass

ClinicalTrials.gov · NCT00668941 · Registry updated: 2017-08-10

Condition / research focus: Osteoporosis
Sponsor: Helen Hayes Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2005-09. Completion: 2017-11 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug)
Alendronate (drug)
Calcium (dietary_supplement)
Vitamin D3 (dietary_supplement)

Where the study takes place — 1 listed sites

Helen Hayes Hospital
West Haverstraw, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis

ClinicalTrials.gov · NCT01153425 · Registry updated: 2017-08-04

Condition / research focus: Osteoporosis, Osteopenia
Sponsor: University of Pennsylvania
Countries with listed sites: United States
Registry dates and results: Start: 2008-07. Completion: 2012-12 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Virtual Bone Biopsy (other) — also listed as: VBB
Teriparatide (drug) — also listed as: Forteo
Zoledronic Acid (drug) — also listed as: Reclast

Where the study takes place — 1 listed sites

University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa

ClinicalTrials.gov · NCT00759772 · Registry updated: 2017-05-11

Condition / research focus: Anorexia Nervosa; Osteoporosis
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2008-09. Completion: 2016-02-22 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo (drug)
Teriparatide (drug)

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women

ClinicalTrials.gov · NCT00361595 · Registry updated: 2017-04-21

Condition / research focus: Osteoporosis
Sponsor: The Cleveland Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2006-08. Completion: 2008-04 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

zoledronic acid (drug) — also listed as: zometa

Where the study takes place — 1 listed sites

The Cleveland Clinic Foundation
Cleveland, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

ClinicalTrials.gov · NCT01400516 · Registry updated: 2017-04-11

Condition / research focus: Rheumatoid Arthritis
Sponsor: Brigham and Women's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2011-08. Completion: 2016-07-28 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug) — also listed as: Forteo
calcium citrate (drug)
Vitamin D (drug)
TNF antagonist (drug)

Where the study takes place — 3 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
Brigham and Women's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
University of Massachusetts Medical School
Worcester, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

ClinicalTrials.gov · NCT01750086 · Registry updated: 2017-03-27

Condition / research focus: Postmenopausal Osteoporosis
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2013-01. Completion: 2014-08 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide 40-mcg subcutaneous injection (drug) — also listed as: Forteo®
Denosumab Injection (drug)
Alendronate Oral Tablet (drug)

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

ClinicalTrials.gov · NCT01343004 · Registry updated: 2017-03-01

Condition / research focus: Osteoporosis; Postmenopausal Osteoporosis
Sponsor: Radius Health, Inc.
Countries with listed sites: Argentina · Brazil · Czechia · Denmark · Estonia · Hong Kong · Lithuania · Poland · Romania · United States
Registry dates and results: Start: 2011-04. Completion: 2014-10 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo (drug)
BA058 80 mcg (drug) — also listed as: abaloparatide, Abaloparatide-SC
teriparatide (drug) — also listed as: Forteo, Forsteo

Where the study takes place — 28 listed sites

Facility not reported
Lakewood, Colorado, United States
Site recruitment: Not reported
Facility not reported
Miami, Florida, United States
Site recruitment: Not reported
Facility not reported
North Miami, Florida, United States
Site recruitment: Not reported
Facility not reported
Atlanta, Georgia, United States
Site recruitment: Not reported
Facility not reported
Bethesda, Maryland, United States
Site recruitment: Not reported
Facility not reported
Buenos Aires, Argentina
Site recruitment: Not reported
Facility not reported
Brasília, Brazil
Site recruitment: Not reported
Facility not reported
Curitiba, Brazil
Site recruitment: Not reported
Facility not reported
Rio de Janeiro, Brazil
Site recruitment: Not reported
Facility not reported
São Paulo, Brazil
Site recruitment: Not reported
Facility not reported
Vitória, Brazil
Site recruitment: Not reported
Facility not reported
Brno, Czechia
Site recruitment: Not reported
Facility not reported
Pardubice, Czechia
Site recruitment: Not reported
Facility not reported
Prague, Czechia
Site recruitment: Not reported
Facility not reported
Aalborg, Denmark
Site recruitment: Not reported
Facility not reported
Ballerup Municipality, Denmark
Site recruitment: Not reported
Facility not reported
Vejle, Denmark
Site recruitment: Not reported
Facility not reported
Tallinn, Estonia
Site recruitment: Not reported
Facility not reported
Tartu, Estonia
Site recruitment: Not reported
Facility not reported
Hong Kong, Hong Kong
Site recruitment: Not reported
Facility not reported
Vilnius, Lithuania
Site recruitment: Not reported
Facility not reported
Bialystok, Poland
Site recruitment: Not reported
Facility not reported
Katowice, Poland
Site recruitment: Not reported
Facility not reported
Kielce, Poland
Site recruitment: Not reported
Facility not reported
Lodz, Poland
Site recruitment: Not reported
Facility not reported
Warsaw, Poland
Site recruitment: Not reported
Facility not reported
Zgierz, Poland
Site recruitment: Not reported
Facility not reported
Bucharest, Romania
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Phase I Study of AK159 in Healthy Postmenopausal Women

ClinicalTrials.gov · NCT01935479 · Registry updated: 2017-02-15

Condition / research focus: Osteoporosis
Sponsor: Asahi Kasei Therapeutics Corporation
Countries with listed sites: Japan
Registry dates and results: Start: 2013-08. Completion: 2014-02 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AK159 (drug)
MN-10-T (drug)
Placebo (drug)

Where the study takes place — 3 listed sites

Facility not reported
Fukuoka, Japan
Site recruitment: Not reported
Facility not reported
Kumamoto, Japan
Site recruitment: Not reported
Facility not reported
Sumida City, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

The Relationship Between the Residual Renal Function and Osteoporosis Treatment

ClinicalTrials.gov · NCT02304887 · Registry updated: 2016-11-25

Condition / research focus: Osteoporosis
Sponsor: Toshihiko Kono
Countries with listed sites: Japan
Registry dates and results: Start: 2006-01. Completion: 2019-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bis, SERM Teriparatide, Denosumab (drug)

Where the study takes place — 1 listed sites

Tomidahama Hospital
Yokkaichi, Mie-ken, Japan
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur

ClinicalTrials.gov · NCT01309399 · Registry updated: 2016-11-23

Condition / research focus: Osteoporosis
Sponsor: Health Research, Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2010-08. Completion: 2015-08 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug) — also listed as: forteo
placebo (other)

Where the study takes place — 1 listed sites

Helen Hayes Hospital
West Haverstraw, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Ankle Fractures Treated With Teriparatide

ClinicalTrials.gov · NCT02955056 · Registry updated: 2016-11-04

Condition / research focus: Fracture, Ankle
Sponsor: Nottingham University Hospitals NHS Trust
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2016-10. Completion: 2017-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Forsteo (drug) — also listed as: Teriparatide hormone

Where the study takes place — 1 listed sites

Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Effects of Teriparatide Therapy for Japanese

ClinicalTrials.gov · NCT01956461 · Registry updated: 2016-10-19

Condition / research focus: Osteoporosis
Sponsor: Tomidahama Hospital
Countries with listed sites: Japan
Registry dates and results: Start: 2010-09. Completion: 2017-10 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Tomidahama Hospital
Yokkaichi, Mie-ken, Japan
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 18:28 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3CompletedINTERVENTIONAL

A Comparison of PF708 and Forteo in Osteoporosis Patients

ClinicalTrials.gov · NCT03002428 · Registry updated: 2018-05-23

Condition / research focus: Osteoporosis
Sponsor: Pfenex, Inc
Countries with listed sites: United States
Registry dates and results: Start: 2016-12. Completion: 2018-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (PF708) (drug)
Teriparatide (Forteo) (drug)

Where the study takes place — 26 listed sites

Radiant Research
Birmingham, Alabama, United States
Site recruitment: Not reported
The Orthopaedic Group
Mobile, Alabama, United States
Site recruitment: Not reported
Radiant Research
Chandler, Arizona, United States
Site recruitment: Not reported
Radiant Research
Mesa, Arizona, United States
Site recruitment: Not reported
SunValley Arthritis Center
Peoria, Arizona, United States
Site recruitment: Not reported
Radiant Research
Phoenix, Arizona, United States
Site recruitment: Not reported
Radiant Research
Colorado Springs, Colorado, United States
Site recruitment: Not reported
OB-GYN Associates of Mid-Florida
Leesburg, Florida, United States
Site recruitment: Not reported
Atlanta Research Center
Atlanta, Georgia, United States
Site recruitment: Not reported
Radiant Research
Chicago, Illinois, United States
Site recruitment: Not reported
Radiant Research
Bridgeton, Missouri, United States
Site recruitment: Not reported
Radiant Research
Papillion, Nebraska, United States
Site recruitment: Not reported
Radiant Research
Henderson, Nevada, United States
Site recruitment: Not reported
Radiant Research
Las Vegas, Nevada, United States
Site recruitment: Not reported
New Mexico Clinical Research & Osteoporosis Center
Albuquerque, New Mexico, United States
Site recruitment: Not reported
Lillestol Research
Fargo, North Dakota, United States
Site recruitment: Not reported
Radiant Research
Akron, Ohio, United States
Site recruitment: Not reported
Radiant Research
Cincinnati, Ohio, United States
Site recruitment: Not reported
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
Site recruitment: Not reported
Pennsylvania Regional Center for Arthritis & Osteoporosis Research
Wyomissing, Pennsylvania, United States
Site recruitment: Not reported
Radiant Research
Dallas, Texas, United States
Site recruitment: Not reported
Radiant Research
Plano, Texas, United States
Site recruitment: Not reported
Radiant Research
San Antonio, Texas, United States
Site recruitment: Not reported
Radiant Research
San Antonio, Texas, United States
Site recruitment: Not reported
Spectrum Medical
Danville, Virginia, United States
Site recruitment: Not reported
Radiant Research
Puyallup, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Secondary Prevention of Osteoporotic Fractures: a Multiple Center Fracture Liaison Service in Greece

ClinicalTrials.gov · NCT02637180 · Registry updated: 2018-02-23

Condition / research focus: Osteoporosis
Sponsor: Hellenic Society for the Study of Bone Metabolism
Countries with listed sites: Greece
Registry dates and results: Start: 2015-04. Completion: 2017-12-07 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

anti-osteoporotic medication (drug) — also listed as: all available anti-osteoporotic medication

Where the study takes place — 4 listed sites

NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, MEDICAL SCHOOL, 2nd DEPARTMENT OF ORTHOPAEDIC SURGERY
Athens, Attica, Greece
Site recruitment: Not reported
Democritus University of Thrace, School of Medicine, Department of Orthopaedic Surgery
Alexandroupoli, Evros, Greece
Site recruitment: Not reported
Orthopaedic Department, Faculty of Medicine, School of Health Sciences, University of Thessalia
Larissa, Greece
Site recruitment: Not reported
Aristotle University of Thessaloniki, 3rd University Orthopaedic Department, Papageorgiou General Hospital
Thessaloniki, Greece
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

ClinicalTrials.gov · NCT01279187 · Registry updated: 2018-02-07

Condition / research focus: Implant
Sponsor: University of Michigan
Countries with listed sites: United States
Registry dates and results: Start: 2011-02. Completion: 2015-11 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug) — also listed as: Forteo
Placebo (drug) — also listed as: carrier

Where the study takes place — 1 listed sites

Michigan Center for Oral Health Research
Ann Arbor, Michigan, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects

ClinicalTrials.gov · NCT02571140 · Registry updated: 2018-01-10

Condition / research focus: Drug Safety and Bioavailability
Sponsor: Entera Bio Ltd.
Countries with listed sites: No country reported
Registry dates and results: Start: 2013-10. Completion: 2017-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug)
Oral PTH (1-34) (drug) — also listed as: Teriparatide

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Fracture (FX) Improvement With Teriparatide: FiX-IT Study

ClinicalTrials.gov · NCT01705587 · Registry updated: 2017-12-12

Condition / research focus: Osteoporosis; Atypical Femoral Fracture
Sponsor: Susan L. Greenspan
Countries with listed sites: United States
Registry dates and results: Start: 2012-12. Completion: 2016-09 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

teriparatide (drug) — also listed as: Forteo

Where the study takes place — 1 listed sites

University of Pittsburgh, Osteoporosis Prevention & Treatment Center
Pittsburgh, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.

ClinicalTrials.gov · NCT00471237 · Registry updated: 2017-11-07

Condition / research focus: Osteoporosis
Sponsor: GlaxoSmithKline
Countries with listed sites: Argentina · Australia · Belgium · Denmark · Germany · Hong Kong · Mexico · Norway · Poland · Russia · South Africa · South Korea · Spain · United States
Registry dates and results: Start: 2007-05-14. Completion: 2008-12-26 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ronacaleret (drug) — also listed as: SB-751689
Teriparatide (drug)
Alendronate (drug)

Where the study takes place — 49 listed sites

GSK Investigational Site
Oakland, California, United States
Site recruitment: Not reported
GSK Investigational Site
Palm Desert, California, United States
Site recruitment: Not reported
GSK Investigational Site
Walnut Creek, California, United States
Site recruitment: Not reported
GSK Investigational Site
Decatur, Georgia, United States
Site recruitment: Not reported
GSK Investigational Site
Bethesda, Maryland, United States
Site recruitment: Not reported
GSK Investigational Site
Akron, Ohio, United States
Site recruitment: Not reported
GSK Investigational Site
Cleveland, Ohio, United States
Site recruitment: Not reported
GSK Investigational Site
Portland, Oregon, United States
Site recruitment: Not reported
GSK Investigational Site
Duncansville, Pennsylvania, United States
Site recruitment: Not reported
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Site recruitment: Not reported
GSK Investigational Site
Buenos Aires, Argentina
Site recruitment: Not reported
GSK Investigational Site
Buenos Aires, Argentina
Site recruitment: Not reported
GSK Investigational Site
St Leonards, New South Wales, Australia
Site recruitment: Not reported
GSK Investigational Site
Footscray, Victoria, Australia
Site recruitment: Not reported
GSK Investigational Site
Geelong, Victoria, Australia
Site recruitment: Not reported
GSK Investigational Site
Heidelberg, Victoria, Australia
Site recruitment: Not reported
GSK Investigational Site
Ghent, Belgium
Site recruitment: Not reported
GSK Investigational Site
Liège, Belgium
Site recruitment: Not reported
GSK Investigational Site
Tienen, Belgium
Site recruitment: Not reported
GSK Investigational Site
Ballerup Municipality, Denmark
Site recruitment: Not reported
GSK Investigational Site
Frankfurt am Main, Hesse, Germany
Site recruitment: Not reported
GSK Investigational Site
Berlin, Germany
Site recruitment: Not reported
GSK Investigational Site
Berlin, Germany
Site recruitment: Not reported
GSK Investigational Site
Berlin, Germany
Site recruitment: Not reported
GSK Investigational Site
Berlin, Germany
Site recruitment: Not reported
GSK Investigational Site
Hamburg, Germany
Site recruitment: Not reported
GSK Investigational Site
Hamburg, Germany
Site recruitment: Not reported
GSK Investigational Site
Hong Kong, Hong Kong
Site recruitment: Not reported
GSK Investigational Site
Shatin, Hong Kong
Site recruitment: Not reported
GSK Investigational Site
Mexico City, Mexico
Site recruitment: Not reported
GSK Investigational Site
Bergen, Norway
Site recruitment: Not reported
GSK Investigational Site
Hamar, Norway
Site recruitment: Not reported
GSK Investigational Site
Oslo, Norway
Site recruitment: Not reported
GSK Investigational Site
Grudziądz, Poland
Site recruitment: Not reported
GSK Investigational Site
Warsaw, Poland
Site recruitment: Not reported
GSK Investigational Site
Wroclaw, Poland
Site recruitment: Not reported
GSK Investigational Site
Moscow, Russia
Site recruitment: Not reported
GSK Investigational Site
Moscow, Russia
Site recruitment: Not reported
GSK Investigational Site
Panorama, South Africa
Site recruitment: Not reported
GSK Investigational Site
Rosebank, South Africa
Site recruitment: Not reported
GSK Investigational Site
Somerset West, South Africa
Site recruitment: Not reported
GSK Investigational Site
Seoul, South Korea
Site recruitment: Not reported
GSK Investigational Site
Suwon, South Korea
Site recruitment: Not reported
GSK Investigational Site
Barcelona, Spain
Site recruitment: Not reported
GSK Investigational Site
Barcelona, Spain
Site recruitment: Not reported
GSK Investigational Site
Madrid, Spain
Site recruitment: Not reported
GSK Investigational Site
Madrid, Spain
Site recruitment: Not reported
GSK Investigational Site
Santiago de Compostela, Spain
Site recruitment: Not reported
GSK Investigational Site
Santiago de Compostela, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

ClinicalTrials.gov · NCT00542425 · Registry updated: 2017-10-30

Condition / research focus: Osteoporosis
Sponsor: Radius Health, Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2007-04. Completion: 2009-06 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

teriparatide (drug) — also listed as: PTH
Placebo (drug)
BA058 20 µg (drug)
BA058 40 µg (drug)
BA058 80 µg (drug)

Where the study takes place — 1 listed sites

Radius Health, Inc.
Cambridge, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab

ClinicalTrials.gov · NCT02130973 · Registry updated: 2017-08-31

Condition / research focus: Osteoporosis
Sponsor: Health Research, Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2013-08. Completion: 2018-08 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Standard Clinical Practice Regimen (drug) — also listed as: 18 months Forteo followed by 18 months Prolia
Experimental Cyclic Regimen (drug) — also listed as: three separate 6 month cycles of daily Forteo, each followed by one of Prolia

Where the study takes place — 1 listed sites

Helen Hayes Hospital
West Haverstraw, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Cyclic Versus Daily Teriparatide on Bone Mass

ClinicalTrials.gov · NCT00668941 · Registry updated: 2017-08-10

Condition / research focus: Osteoporosis
Sponsor: Helen Hayes Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2005-09. Completion: 2017-11 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug)
Alendronate (drug)
Calcium (dietary_supplement)
Vitamin D3 (dietary_supplement)

Where the study takes place — 1 listed sites

Helen Hayes Hospital
West Haverstraw, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis

ClinicalTrials.gov · NCT01153425 · Registry updated: 2017-08-04

Condition / research focus: Osteoporosis, Osteopenia
Sponsor: University of Pennsylvania
Countries with listed sites: United States
Registry dates and results: Start: 2008-07. Completion: 2012-12 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Virtual Bone Biopsy (other) — also listed as: VBB
Teriparatide (drug) — also listed as: Forteo
Zoledronic Acid (drug) — also listed as: Reclast

Where the study takes place — 1 listed sites

University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa

ClinicalTrials.gov · NCT00759772 · Registry updated: 2017-05-11

Condition / research focus: Anorexia Nervosa; Osteoporosis
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2008-09. Completion: 2016-02-22 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo (drug)
Teriparatide (drug)

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women

ClinicalTrials.gov · NCT00361595 · Registry updated: 2017-04-21

Condition / research focus: Osteoporosis
Sponsor: The Cleveland Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2006-08. Completion: 2008-04 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

zoledronic acid (drug) — also listed as: zometa

Where the study takes place — 1 listed sites

The Cleveland Clinic Foundation
Cleveland, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

ClinicalTrials.gov · NCT01400516 · Registry updated: 2017-04-11

Condition / research focus: Rheumatoid Arthritis
Sponsor: Brigham and Women's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2011-08. Completion: 2016-07-28 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug) — also listed as: Forteo
calcium citrate (drug)
Vitamin D (drug)
TNF antagonist (drug)

Where the study takes place — 3 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
Brigham and Women's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
University of Massachusetts Medical School
Worcester, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

ClinicalTrials.gov · NCT01750086 · Registry updated: 2017-03-27

Condition / research focus: Postmenopausal Osteoporosis
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2013-01. Completion: 2014-08 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide 40-mcg subcutaneous injection (drug) — also listed as: Forteo®
Denosumab Injection (drug)
Alendronate Oral Tablet (drug)

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

ClinicalTrials.gov · NCT01343004 · Registry updated: 2017-03-01

Condition / research focus: Osteoporosis; Postmenopausal Osteoporosis
Sponsor: Radius Health, Inc.
Countries with listed sites: Argentina · Brazil · Czechia · Denmark · Estonia · Hong Kong · Lithuania · Poland · Romania · United States
Registry dates and results: Start: 2011-04. Completion: 2014-10 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo (drug)
BA058 80 mcg (drug) — also listed as: abaloparatide, Abaloparatide-SC
teriparatide (drug) — also listed as: Forteo, Forsteo

Where the study takes place — 28 listed sites

Facility not reported
Lakewood, Colorado, United States
Site recruitment: Not reported
Facility not reported
Miami, Florida, United States
Site recruitment: Not reported
Facility not reported
North Miami, Florida, United States
Site recruitment: Not reported
Facility not reported
Atlanta, Georgia, United States
Site recruitment: Not reported
Facility not reported
Bethesda, Maryland, United States
Site recruitment: Not reported
Facility not reported
Buenos Aires, Argentina
Site recruitment: Not reported
Facility not reported
Brasília, Brazil
Site recruitment: Not reported
Facility not reported
Curitiba, Brazil
Site recruitment: Not reported
Facility not reported
Rio de Janeiro, Brazil
Site recruitment: Not reported
Facility not reported
São Paulo, Brazil
Site recruitment: Not reported
Facility not reported
Vitória, Brazil
Site recruitment: Not reported
Facility not reported
Brno, Czechia
Site recruitment: Not reported
Facility not reported
Pardubice, Czechia
Site recruitment: Not reported
Facility not reported
Prague, Czechia
Site recruitment: Not reported
Facility not reported
Aalborg, Denmark
Site recruitment: Not reported
Facility not reported
Ballerup Municipality, Denmark
Site recruitment: Not reported
Facility not reported
Vejle, Denmark
Site recruitment: Not reported
Facility not reported
Tallinn, Estonia
Site recruitment: Not reported
Facility not reported
Tartu, Estonia
Site recruitment: Not reported
Facility not reported
Hong Kong, Hong Kong
Site recruitment: Not reported
Facility not reported
Vilnius, Lithuania
Site recruitment: Not reported
Facility not reported
Bialystok, Poland
Site recruitment: Not reported
Facility not reported
Katowice, Poland
Site recruitment: Not reported
Facility not reported
Kielce, Poland
Site recruitment: Not reported
Facility not reported
Lodz, Poland
Site recruitment: Not reported
Facility not reported
Warsaw, Poland
Site recruitment: Not reported
Facility not reported
Zgierz, Poland
Site recruitment: Not reported
Facility not reported
Bucharest, Romania
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Phase I Study of AK159 in Healthy Postmenopausal Women

ClinicalTrials.gov · NCT01935479 · Registry updated: 2017-02-15

Condition / research focus: Osteoporosis
Sponsor: Asahi Kasei Therapeutics Corporation
Countries with listed sites: Japan
Registry dates and results: Start: 2013-08. Completion: 2014-02 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AK159 (drug)
MN-10-T (drug)
Placebo (drug)

Where the study takes place — 3 listed sites

Facility not reported
Fukuoka, Japan
Site recruitment: Not reported
Facility not reported
Kumamoto, Japan
Site recruitment: Not reported
Facility not reported
Sumida City, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

The Relationship Between the Residual Renal Function and Osteoporosis Treatment

ClinicalTrials.gov · NCT02304887 · Registry updated: 2016-11-25

Condition / research focus: Osteoporosis
Sponsor: Toshihiko Kono
Countries with listed sites: Japan
Registry dates and results: Start: 2006-01. Completion: 2019-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bis, SERM Teriparatide, Denosumab (drug)

Where the study takes place — 1 listed sites

Tomidahama Hospital
Yokkaichi, Mie-ken, Japan
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur

ClinicalTrials.gov · NCT01309399 · Registry updated: 2016-11-23

Condition / research focus: Osteoporosis
Sponsor: Health Research, Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2010-08. Completion: 2015-08 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teriparatide (drug) — also listed as: forteo
placebo (other)

Where the study takes place — 1 listed sites

Helen Hayes Hospital
West Haverstraw, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Ankle Fractures Treated With Teriparatide

ClinicalTrials.gov · NCT02955056 · Registry updated: 2016-11-04

Condition / research focus: Fracture, Ankle
Sponsor: Nottingham University Hospitals NHS Trust
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2016-10. Completion: 2017-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Forsteo (drug) — also listed as: Teriparatide hormone

Where the study takes place — 1 listed sites

Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Effects of Teriparatide Therapy for Japanese

ClinicalTrials.gov · NCT01956461 · Registry updated: 2016-10-19

Condition / research focus: Osteoporosis
Sponsor: Tomidahama Hospital
Countries with listed sites: Japan
Registry dates and results: Start: 2010-09. Completion: 2017-10 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Tomidahama Hospital
Yokkaichi, Mie-ken, Japan
Site recruitment: Recruiting

Original record, eligibility, contacts and results →